Clinical Trial: An Expanded Access Program of Emicizumab in Participants With Hemophilia A With Inhibitors

Study Status: Available
Recruit Status: Available
Study Type: Expanded Access:   Available for Treatment IND/Protocol

Official Title: An Open-Label, Multicenter, Expanded Access Program for Emicizumab in Patients With Hemophilia A With Inhibitors

Brief Summary: This open-label, multicenter expanded access program (EAP) is designed to provide emicizumab to eligible participants with hemophilia A with factor VIII (FVIII) inhibitors before it is commercially available in the United States for the indication of hemophilia A with FVIII inhibitors. Discontinuation may occur earlier if participant or physician decides to discontinue treatment or the sponsor discontinues emicizumab clinical development.

Detailed Summary:
Sponsor: Genentech, Inc.

Current Primary Outcome:

Original Primary Outcome:

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Genentech, Inc.

Dates:
Date Received: May 12, 2017
Date Started:
Date Completion:
Last Updated: May 12, 2017
Last Verified: May 2017